| 1 | 1 | | II |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION S. 735 |
|---|
| 5 | 5 | | To amend the Public Health Service Act to reauthorize a sickle cell disease |
|---|
| 6 | 6 | | prevention and treatment demonstration program. |
|---|
| 7 | 7 | | IN THE SENATE OF THE UNITED STATES |
|---|
| 8 | 8 | | FEBRUARY26, 2025 |
|---|
| 9 | 9 | | Mr. S |
|---|
| 10 | 10 | | COTTof South Carolina (for himself and Mr. BOOKER) introduced the |
|---|
| 11 | 11 | | following bill; which was read twice and referred to the Committee on |
|---|
| 12 | 12 | | Health, Education, Labor, and Pensions |
|---|
| 13 | 13 | | A BILL |
|---|
| 14 | 14 | | To amend the Public Health Service Act to reauthorize a |
|---|
| 15 | 15 | | sickle cell disease prevention and treatment demonstra- |
|---|
| 16 | 16 | | tion program. |
|---|
| 17 | 17 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 18 | 18 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 19 | 19 | | SECTION 1. SHORT TITLE. 3 |
|---|
| 20 | 20 | | This Act may be cited as the ‘‘Sickle Cell Disease 4 |
|---|
| 21 | 21 | | and Other Heritable Blood Disorders Research, Surveil-5 |
|---|
| 22 | 22 | | lance, Prevention, and Treatment Act of 2025’’. 6 |
|---|
| 23 | 23 | | VerDate Sep 11 2014 22:22 Mar 13, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S735.IS S735 |
|---|
| 24 | 24 | | ssavage on LAPJG3WLY3PROD with BILLS 2 |
|---|
| 25 | 25 | | •S 735 IS |
|---|
| 26 | 26 | | SEC. 2. SICKLE CELL DISEASE PREVENTION AND TREAT-1 |
|---|
| 27 | 27 | | MENT. 2 |
|---|
| 28 | 28 | | (a) I |
|---|
| 29 | 29 | | NGENERAL.—Section 1106(b) of the Public 3 |
|---|
| 30 | 30 | | Health Service Act (42 U.S.C. 300b–5(b)) is amended— 4 |
|---|
| 31 | 31 | | (1) in paragraph (1)(A)(iii), by striking ‘‘pre-5 |
|---|
| 32 | 32 | | vention and treatment of sickle cell disease’’ and in-6 |
|---|
| 33 | 33 | | serting ‘‘treatment of sickle cell disease and the pre-7 |
|---|
| 34 | 34 | | vention and treatment of complications of sickle cell 8 |
|---|
| 35 | 35 | | disease’’; 9 |
|---|
| 36 | 36 | | (2) in paragraph (2)(D), by striking ‘‘preven-10 |
|---|
| 37 | 37 | | tion and treatment of sickle cell disease’’ and insert-11 |
|---|
| 38 | 38 | | ing ‘‘treatment of sickle cell disease and the preven-12 |
|---|
| 39 | 39 | | tion and treatment of complications of sickle cell dis-13 |
|---|
| 40 | 40 | | ease’’; 14 |
|---|
| 41 | 41 | | (3) in paragraph (3)— 15 |
|---|
| 42 | 42 | | (A) in subparagraph (A), by striking 16 |
|---|
| 43 | 43 | | ‘‘enter into a contract with’’ and inserting 17 |
|---|
| 44 | 44 | | ‘‘make a grant to, or enter into a contract or 18 |
|---|
| 45 | 45 | | cooperative agreement with,’’; and 19 |
|---|
| 46 | 46 | | (B) in subparagraph (B), in each of 20 |
|---|
| 47 | 47 | | clauses (ii) and (iii), by striking ‘‘prevention 21 |
|---|
| 48 | 48 | | and treatment of sickle cell disease’’ and insert-22 |
|---|
| 49 | 49 | | ing ‘‘treatment of sickle cell disease and the 23 |
|---|
| 50 | 50 | | prevention and treatment of complications of 24 |
|---|
| 51 | 51 | | sickle cell disease’’; and 25 |
|---|
| 52 | 52 | | VerDate Sep 11 2014 22:22 Mar 13, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S735.IS S735 |
|---|
| 53 | 53 | | ssavage on LAPJG3WLY3PROD with BILLS 3 |
|---|
| 54 | 54 | | •S 735 IS |
|---|
| 55 | 55 | | (4) in paragraph (6), by striking ‘‘$4,455,000 1 |
|---|
| 56 | 56 | | for each of fiscal years 2019 through 2023’’ and in-2 |
|---|
| 57 | 57 | | serting ‘‘$8,205,000 for each of fiscal years 2025 3 |
|---|
| 58 | 58 | | through 2029’’. 4 |
|---|
| 59 | 59 | | (b) S |
|---|
| 60 | 60 | | ENSE OFCONGRESS.—It is the sense of Con-5 |
|---|
| 61 | 61 | | gress that further research should be undertaken to ex-6 |
|---|
| 62 | 62 | | pand the understanding of the causes of, and to find cures 7 |
|---|
| 63 | 63 | | for, heritable blood disorders, including sickle cell disease. 8 |
|---|
| 64 | 64 | | Æ |
|---|
| 65 | 65 | | VerDate Sep 11 2014 22:22 Mar 13, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\S735.IS S735 |
|---|
| 66 | 66 | | ssavage on LAPJG3WLY3PROD with BILLS |
|---|